Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

(2018) Ricardo L. B. Costa et al.   BREAST CANCER RESEARCH AND TREATMENT

Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss?

(2018) Raghavendra Tejo Karthik Poluri et al.   Frontiers in Oncology

Abstract 4531: Development of a companion diagnostic assay for the detection of phosphatase and tensin (PTEN) protein loss and treatment with ipatasertib in metastatic castration-resistant prostatic cancer (mCRPC)

(2018) Crystal Stephens et al.   CANCER RESEARCH

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).

(2018) Rebecca Dent et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

(2018) Johann S. de Bono et al.   CLINICAL CANCER RESEARCH

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2017) Sung-Bae Kim et al.   LANCET ONCOLOGY

PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)

(2016) J.S. de Bono et al.   ANNALS OF ONCOLOGY

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

(2016) Patricia Mucci LoRusso   JOURNAL OF CLINICAL ONCOLOGY

Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer

(2016) Ebubekir Dirican et al.   TUMOR BIOLOGY

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

(2016) Cristina Saura et al.   Cancer Discovery

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

(2015) Roberta Ferraldeschi et al.   EUROPEAN UROLOGY

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance

(2014) AndrewC Hsieh et al.   ASIAN JOURNAL OF ANDROLOGY

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

(2013) J. Lin et al.   CLINICAL CANCER RESEARCH

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

(2013) Y. Yan et al.   CLINICAL CANCER RESEARCH

Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer

(2013) Rhonda L Bitting et al.   ENDOCRINE-RELATED CANCER

Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors

(2012) James F. Blake et al.   JOURNAL OF MEDICINAL CHEMISTRY

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

(2011) Brett S. Carver et al.   CANCER CELL

PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches

(2011) Giovanni Ligresti et al.   CELL CYCLE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER